Founding Cardiologist The Animal Cardiology Center New York, New York, United States
Disclosure(s):
Justin A. Carlson, DACVIM (Cardiology): No financial relationships to disclose
Presentation Description / Summary: An ARNi is a combination medication comprised of an angiotensin receptor blocker and a neprilysin inhibitor. Sacubitril/valsartan (Entresto®) is a first in class ARNi that has been shown in human medicine to significantly decrease cardiac death and heart failure hospitalization compared to ACEi (enalapril). It is stated in the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure that all patients who tolerate an ace inhibitor should be switched to an ARNi. The Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM) trial was stopped early, after a median follow-up of 27 months, because the boundary for an overwhelming benefit for ARNi had been crossed. There is limited published data in veterinary medicine on the use of ARNi, but anecdotal data, popularity, and clinical use of sacubitril/valsartan in veterinary medicine is increasing. This presentation will focus on use of ARNi in veterinary medicine based upon the presenters’ experience over the last two years with data and statistics from this cohort of 49 patients. The speaker will discuss his approach to utilizing Entresto in the canine patient. Participation from the audience in the form of questions will be encouraged.
Learning Objectives:
After completion participants will learn more about ARNIs in veterinary medicine from the speaker's experiences.
After completion participants will feel more comfortable using this newer group of medication.
